Trials / Completed
CompletedNCT02653976
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Solasia Pharma K.K. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-02L (darinaparsin for injection) | Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days |
Timeline
- Start date
- 2016-03-25
- Primary completion
- 2020-10-11
- Completion
- 2021-06-17
- First posted
- 2016-01-13
- Last updated
- 2024-01-26
- Results posted
- 2024-01-26
Locations
24 sites across 4 countries: Hong Kong, Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02653976. Inclusion in this directory is not an endorsement.